Porphyric neuropathy: prevention of progression using haeme-arginate.
We report on a patient with acute intermittent porphyria (AIP) who, during treatment with hypertonic glucose, developed peripheral neuropathy. Once haeme-arginate was started, the progression of the neuropathy was attenuated. This suggests that hypertonic glucose may be inadequate in preventing the development of neuropathy in a patient with porphyria. However, haeme-arginate, if started early, can attenuate the progression of porphyric neuropathy.
Muthane
U B
UB
Department of Neurology, St John's Medical College and Hospital, Bangalore, India.
Vengamma
B
B
Bharathi
K C
KC
Mamatha
P
P
D000328:Adult; D001120:Arginine / Q000627:therapeutic use*; D005950:Glucose Solution, Hypertonic / Q000627:therapeutic use; D006418:Heme / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D017118:Porphyria, Acute Intermittent / Q000150:complications / Q000188:drug therapy*
D005950:Glucose Solution, Hypertonic; D006418:Heme; D001120:Arginine; C048849:heme arginate